Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GENinCode UK Ltd. ( (GB:GENI) ) has issued an update.
GENinCode UK Ltd. has successfully raised £4.0 million through the issuance of new ordinary shares at 3.7 pence per share, a 5.1% discount from the prior day’s closing price. The fundraising, which involves a placing and subscription, will enhance the company’s financial position, supporting its strategic initiatives in the genomic healthcare sector. The new shares are expected to begin trading on the AIM market of the London Stock Exchange in early March 2025, contingent upon shareholder approval at an upcoming General Meeting.
More about GENinCode UK Ltd.
GENinCode UK Ltd. operates in the healthcare industry, specializing in genetic testing and risk assessment services. The company focuses on providing innovative solutions for the prediction and prevention of cardiovascular disease, leveraging advanced genomic technologies to improve patient outcomes.
YTD Price Performance: 2.63%
Average Trading Volume: 592,410
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £6.9M
Learn more about GENI stock on TipRanks’ Stock Analysis page.